Paying user area
Try for free
Bristol-Myers Squibb Co. pages available for free this week:
- Cash Flow Statement
- Common-Size Balance Sheet: Assets
- Analysis of Profitability Ratios
- Analysis of Geographic Areas
- Enterprise Value (EV)
- Enterprise Value to EBITDA (EV/EBITDA)
- Enterprise Value to FCFF (EV/FCFF)
- Return on Assets (ROA) since 2005
- Debt to Equity since 2005
- Price to Earnings (P/E) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Bristol-Myers Squibb Co. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Revenues as Reported
12 months ended: | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Net product sales | |||||||||||
Alliance revenues | |||||||||||
Other revenues | |||||||||||
Revenues |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
- Net Product Sales
- Net product sales displayed an overall increasing trend over the five-year period. The value rose from 41,321 million USD in 2020 to 46,778 million USD in 2024. There was a steady increase from 2020 to 2021, a slight decline in 2022, followed by another small decrease in 2023, before increasing notably in 2024. This suggests strong core product performance despite modest fluctuations in the middle years.
- Alliance Revenues
- Alliance revenues experienced a fluctuating but generally downward trend. Beginning at 615 million USD in 2020, revenues increased to 716 million USD in 2021 and 742 million USD in 2022, but then declined to 608 million USD in 2023 and further dropped to 479 million USD in 2024. This indicates a decrease in income from partnerships or licensing agreements toward the end of the period.
- Other Revenues
- Other revenues showed notable variability, with an initial increase from 582 million USD in 2020 to 746 million USD in 2022. However, a decline occurred in 2023 down to 620 million USD, followed by a significant jump to 1,043 million USD in 2024. This pattern reflects volatility in non-core revenue sources, with a substantial increase in the latest year that could indicate new income streams or one-time gains.
- Total Revenues
- Total revenues generally mirrored the trends seen in net product sales. Starting at 42,518 million USD in 2020, revenues increased to 46,385 million USD in 2021, then slightly decreased over the next two years, reaching 45,006 million USD in 2023. In 2024, total revenues rose sharply to 48,300 million USD. The recovery and growth in 2024 suggest an overall positive revenue trend despite intermediate volatility in alliance and other revenue streams.